The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...

The PHASE 3 REVISIT study has demonstrated that aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ventilator-associated pneumonia ...